Social and Economic Outcomes of HIV/AIDS Care and Treatment in HIV Infected South African Adults
NCT ID: NCT00270764
Last Updated: 2013-11-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1065 participants
OBSERVATIONAL
2005-07-31
2013-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* the degree of functional impairment among patients seeking care for HIV/AIDS,
* the impact of treatment on the ability of patients to perform normal daily activities and attend work,
* the full economic costs to patients of obtaining treatment,
* the impact of treatment on sources of household income,
* social and economic correlates of adherence to therapy, and
* the cost of delivering ART to different types of patients in diverse settings.
The study will last 4 years and will comprise a one-year cross-sectional analysis and a three-year longitudinal analysis. Data will be collected from questionnaires administered during patients' routine visits to public and non-governmental organization-based HIV clinics in South Africa. In accordance with current South African national treatment guidelines, patients who have started ART will visit a clinic every 3 months during the longitudinal analysis for a total of 12 visits; patients not yet on ART will visit a clinic every 6 months for a total of 6 visits.
Questionnaire responses will be matched to indicators of disease progression and treatment history drawn from patients' medical records. The initial one-year analysis will compare outcomes for groups of patients stratified by disease stage and treatment duration. Longitudinal analysis will compare outcomes before and after the initiation of ART; each participant's responses and medical outcomes will be compared with his or her own previous results and with those of other participants at a similar stage of disease progression or treatment duration. This study will generate information needed to sustain large-scale treatment interventions, improve the focus and management of treatment delivery programs, and provide a better understanding of barriers to treatment adherence among HIV infected South African patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Full cohort
Adult ART patients at 3 treatment facilities in South Africa
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willing to accept ART if medically eligible according to South Africa's national treatment guidelines
Exclusion Criteria
* On ART for more than 6 months at the time of study entry
* Refuse to accept ART despite medical eligibility
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
United States Agency for International Development (USAID)
FED
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sydney B. Rosen, MPA
Role: PRINCIPAL_INVESTIGATOR
Boston University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Health Economics Research Office, Helen Joseph Hospital
Johannesburg, Gauteng, South Africa
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Beard J, Feeley F, Rosen S. Economic and quality of life outcomes of antiretroviral therapy for HIV/AIDS in developing countries: a systematic literature review. AIDS Care. 2009 Nov;21(11):1343-56. doi: 10.1080/09540120902889926.
Rosen S, Ketlhapile M, Sanne I, Desilva MB. Differences in normal activities, job performance and symptom prevalence between patients not yet on antiretroviral therapy and patients initiating therapy in South Africa. AIDS. 2008 Jul;22 Suppl 1:S131-9. doi: 10.1097/01.aids.0000327634.92844.91.
Rosen S, Ketlhapile M, Sanne I, DeSilva MB. Characteristics of patients accessing care and treatment for HIV/AIDS at public and nongovernmental sites in South Africa. J Int Assoc Physicians AIDS Care (Chic). 2008 Jul-Aug;7(4):200-7. doi: 10.1177/1545109708320684. Epub 2008 Jul 14.
Rosen S, Ketlhapile M, Sanne I, DeSilva MB. Cost to patients of obtaining treatment for HIV/AIDS in South Africa. S Afr Med J. 2007 Jul;97(7):524-9.
Rosen S, Larson B, Brennan A, Long L, Fox M, Mongwenyana C, Ketlhapile M, Sanne I. Economic outcomes of patients receiving antiretroviral therapy for HIV/AIDS in South Africa are sustained through three years on treatment. PLoS One. 2010 Sep 14;5(9):e12731. doi: 10.1371/journal.pone.0012731.
Rosen S, Larson B, Rohr J, Sanne I, Mongwenyana C, Brennan AT, Galarraga O. Effect of antiretroviral therapy on patients' economic well being: five-year follow-up. AIDS. 2014 Jan 28;28(3):417-24. doi: 10.1097/QAD.0000000000000053.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PEPFAR 13
Identifier Type: -
Identifier Source: org_study_id